VireturnRevenue
12B USDAnnual · FY 2025VRTX
VERTEX PHARMACEUTICALS INC / MA
Operating income
4.2B USDAnnual · FY 2025Net income
4B USDAnnual · FY 2025Total assets
25.6B USDAnnual · FY 2025Equity
18.7B USDAnnual · FY 2025Operating cash flow
3.6B USDAnnual · FY 2025VRTX · Chart
Chart provided by TradingView. Loading the chart connects your browser to TradingView and sends necessary technical information such as your IP address, page URL, and displayed symbol.
Reported financial information
Revenue
USD
12B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 7.6B USD |
| FY 2022 | 8.9B USD |
| FY 2023 | 9.9B USD |
| FY 2024 | 11B USD |
| FY 2025 | 12B USD |
Operating income
USD
4.2B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 2.8B USD |
| FY 2022 | 4.3B USD |
| FY 2023 | 3.8B USD |
| FY 2024 | -232.9M USD |
| FY 2025 | 4.2B USD |
Net income
USD
4B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 2.3B USD |
| FY 2022 | 3.3B USD |
| FY 2023 | 3.6B USD |
| FY 2024 | -535.6M USD |
| FY 2025 | 4B USD |
Total assets
USD
25.6B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 13.4B USD |
| FY 2022 | 18.2B USD |
| FY 2023 | 22.7B USD |
| FY 2024 | 22.5B USD |
| FY 2025 | 25.6B USD |
Equity
USD
18.7B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 10.1B USD |
| FY 2022 | 13.9B USD |
| FY 2023 | 17.6B USD |
| FY 2024 | 16.4B USD |
| FY 2025 | 18.7B USD |
Operating cash flow
USD
3.6B USD
Period data
| Period | Value |
|---|---|
| FY 2021 | 2.6B USD |
| FY 2022 | 4.1B USD |
| FY 2023 | 3.5B USD |
| FY 2024 | -492.6M USD |
| FY 2025 | 3.6B USD |
Revenue growth
%
8.9%
Period data
| Period | Value |
|---|---|
| FY 2021 | 22.1% |
| FY 2022 | 17.9% |
| FY 2023 | 10.5% |
| FY 2024 | 11.7% |
| FY 2025 | 8.9% |
Operating income growth
%
Loss → Profit
Period data
| Period | Value |
|---|---|
| FY 2021 | -2.6% |
| FY 2022 | 54.8% |
| FY 2023 | -11% |
| FY 2024 | Profit → Loss |
| FY 2025 | Loss → Profit |
Net income growth
%
Loss → Profit
Period data
| Period | Value |
|---|---|
| FY 2021 | -13.6% |
| FY 2022 | 41.8% |
| FY 2023 | 9% |
| FY 2024 | Profit → Loss |
| FY 2025 | Loss → Profit |
Operating margin
%
34.8%
Period data
| Period | Value |
|---|---|
| FY 2021 | 36.7% |
| FY 2022 | 48.2% |
| FY 2023 | 38.8% |
| FY 2024 | -2.1% |
| FY 2025 | 34.8% |
Net margin
%
32.9%
Period data
| Period | Value |
|---|---|
| FY 2021 | 30.9% |
| FY 2022 | 37.2% |
| FY 2023 | 36.7% |
| FY 2024 | -4.9% |
| FY 2025 | 32.9% |
Return on assets
%
16.4%
Period data
| Period | Value |
|---|---|
| FY 2021 | 18.6% |
| FY 2022 | 21% |
| FY 2023 | 17.7% |
| FY 2024 | -2.4% |
| FY 2025 | 16.4% |
Debt/Equity
x
0.37x
Period data
| Period | Value |
|---|---|
| FY 2021 | 0.33x |
| FY 2022 | 0.3x |
| FY 2023 | 0.29x |
| FY 2024 | 0.37x |
| FY 2025 | 0.37x |